You just read:

DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)

News provided by

DelMar Pharmaceuticals, Inc.

13 Feb, 2017, 08:40 ET